Esophageal Cancer – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Esophageal Cancer – Pipeline Review, H1 2017’, provides an overview of the Esophageal Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Esophageal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Esophageal Cancer and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Esophageal Cancer

The report reviews pipeline therapeutics for Esophageal Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Esophageal Cancer therapeutics and enlists all their major and minor projects

The report assesses Esophageal Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Esophageal Cancer

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Esophageal Cancer

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Esophageal Cancer pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Adaptimmune Therapeutics Plc

ADC Therapeutics Sarl

Aduro BioTech Inc

Advaxis Inc

Advenchen Laboratories LLC

Almac Discovery Ltd

Amgen Inc

Aprea AB

ArQule Inc

Array BioPharma Inc

Aslan Pharmaceuticals Pte Ltd

ATLAB Pharma SAS

Bayer AG

BeiGene Ltd

Beta Pharma Inc

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

CBT Pharmaceuticals Inc

Celgene Corp

Celldex Therapeutics Inc

Cellectar Biosciences Inc

CellSeed Inc

Clovis Oncology Inc

Cyclacel Pharmaceuticals Inc

Eli Lilly and Company

F. Hoffmann-La Roche Ltd

Genmab A/S

GlaxoSmithKline Plc

Glycotope GmbH

Hutchison China MediTech Ltd

Ignyta Inc

Immunocore Ltd

ImmunoFrontier Inc

Immunomedics Inc

Intezyne Technologies Inc

Jiangsu Hengrui Medicine Co Ltd

Johnson & Johnson

Komipharm International Co Ltd

Leap Therapeutics Inc

MaxiVAX SA

Mebiopharm Co Ltd

MedImmune LLC

Merck & Co Inc

Novartis AG

Omeros Corp

Oncolys BioPharma Inc

OncoMed Pharmaceuticals Inc

Ono Pharmaceutical Co Ltd

Puma Biotechnology Inc

Rhizen Pharmaceuticals SA

Shionogi & Co Ltd

Spectrum Pharmaceuticals Inc

Stelic Institute & Co Inc

Supratek Pharma Inc

Symphogen A/S

Taiho Pharmaceutical Co Ltd

Taiwan Liposome Company Ltd

Takara Bio Inc

Transgene Biotek Ltd

VioQuest Pharmaceuticals Inc

XuanZhu Pharma Co Ltd

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 9

Global Markets Direct Report Coverage 9

Esophageal Cancer - Overview 10

Esophageal Cancer - Therapeutics Development 11

Pipeline Overview 11

Pipeline by Companies 12

Pipeline by Universities/Institutes 17

Products under Development by Companies 18

Products under Development by Universities/Institutes 23

Esophageal Cancer - Therapeutics Assessment 24

Assessment by Target 24

Assessment by Mechanism of Action 28

Assessment by Route of Administration 32

Assessment by Molecule Type 34

Esophageal Cancer - Companies Involved in Therapeutics Development 36

Adaptimmune Therapeutics Plc 36

ADC Therapeutics Sarl 36

Aduro BioTech Inc 37

Advaxis Inc 37

Advenchen Laboratories LLC 38

Almac Discovery Ltd 38

Amgen Inc 39

Aprea AB 39

ArQule Inc 40

Array BioPharma Inc 40

Aslan Pharmaceuticals Pte Ltd 41

ATLAB Pharma SAS 41

Bayer AG 42

BeiGene Ltd 42

Beta Pharma Inc 43

Boehringer Ingelheim GmbH 43

Bristol-Myers Squibb Company 44

CBT Pharmaceuticals Inc 44

Celgene Corp 45

Celldex Therapeutics Inc 45

Cellectar Biosciences Inc 46

CellSeed Inc 46

Clovis Oncology Inc 47

Cyclacel Pharmaceuticals Inc 47

Eli Lilly and Company 48

F. Hoffmann-La Roche Ltd 48

Genmab A/S 49

GlaxoSmithKline Plc 49

Glycotope GmbH 50

Hutchison China MediTech Ltd 50

Ignyta Inc 51

Immunocore Ltd 51

ImmunoFrontier Inc 52

Immunomedics Inc 52

Intezyne Technologies Inc 53

Jiangsu Hengrui Medicine Co Ltd 53

Johnson & Johnson 54

Komipharm International Co Ltd 54

Leap Therapeutics Inc 55

MaxiVAX SA 55

Mebiopharm Co Ltd 56

MedImmune LLC 56

Merck & Co Inc 57

Novartis AG 57

Omeros Corp 58

Oncolys BioPharma Inc 58

OncoMed Pharmaceuticals Inc 59

Ono Pharmaceutical Co Ltd 60

Puma Biotechnology Inc 60

Rhizen Pharmaceuticals SA 61

Shionogi & Co Ltd 61

Spectrum Pharmaceuticals Inc 62

Stelic Institute & Co Inc 62

Supratek Pharma Inc 63

Symphogen A/S 63

Taiho Pharmaceutical Co Ltd 64

Taiwan Liposome Company Ltd 64

Takara Bio Inc 65

Transgene Biotek Ltd 65

VioQuest Pharmaceuticals Inc 66

XuanZhu Pharma Co Ltd 66

Esophageal Cancer - Drug Profiles 67

(tipiracil hydrochloride + trifluridine) - Drug Profile 67

1-BB1 - Drug Profile 73

ADCT-502 - Drug Profile 74

ADXS-HER2 - Drug Profile 75

afatinib dimaleate - Drug Profile 79

AL-3818 - Drug Profile 93

ALM-301 - Drug Profile 96

apatinib - Drug Profile 97

APR-246 - Drug Profile 101

atezolizumab - Drug Profile 105

ATL-101 - Drug Profile 122

BGBA-317 - Drug Profile 125

binimetinib - Drug Profile 127

brontictuzumab - Drug Profile 135

CBT-501 - Drug Profile 139

CDX-1401 - Drug Profile 141

Cellular Immunotherapy 1 for Esophageal Cancer - Drug Profile 144

Cellular Immunotherapy for Esophageal Cancer - Drug Profile 145

Cellular Immunotherapy for Oncology - Drug Profile 146

Cellular Immunotherapy for Oncology - Drug Profile 147

Cellular Immunotherapy for Oncology - Drug Profile 148

Cellular Immunotherapy to Target CD-3 and HER-2 for Oncology - Drug Profile 150

Cellular Immunotherapy to Target EPCAM for Oncology - Drug Profile 151

Cellular Immunotherapy to Target HER-2 for Advanced Malignancy and Metastatic Cancer - Drug Profile 152

Cellular Immunotherapy to Target MAGEA4 for Oncology - Drug Profile 153

Cellular Immunotherapy to Target NY-ESO 1 for Oncology - Drug Profile 155

cetuximab biobetter - Drug Profile 156

CGX-1321 - Drug Profile 158

CLS-2702C - Drug Profile 159

CRS-207 - Drug Profile 160

CYC-140 - Drug Profile 167

DKN-01 - Drug Profile 169

donafenib - Drug Profile 172

doxorubicin - Drug Profile 173

durvalumab - Drug Profile 174

elgemtumab - Drug Profile 188

erdafitinib - Drug Profile 190

futuximab + modotuximab - Drug Profile 192

ganetespib - Drug Profile 196

GSK-2256098 - Drug Profile 209

GSK-3359609 - Drug Profile 211

GSK-3377794 - Drug Profile 212

HKT-288 - Drug Profile 220

HMPL-309 - Drug Profile 221

I131-CLR1404 - Drug Profile 222

IBI-308 - Drug Profile 229

icotinib hydrochloride - Drug Profile 230

IMF-001 - Drug Profile 232

ipilimumab + nivolumab - Drug Profile 233

IT-139 - Drug Profile 238

JNJ-63723283 - Drug Profile 240

JS-001 - Drug Profile 241

KML-001 - Drug Profile 242

LY-3143921 - Drug Profile 244

MEDI-3622 - Drug Profile 245

Monoclonal Antibodies to Inhibit PD-L2 for Esophageal Cancer - Drug Profile 246

MVXONCO-1 - Drug Profile 247

neratinib - Drug Profile 249

nimotuzumab - Drug Profile 267

nintedanib - Drug Profile 271

nivolumab - Drug Profile 282

OBP-301 - Drug Profile 322

oxaliplatin - Drug Profile 324

paclitaxel albumin bound - Drug Profile 325

panitumumab - Drug Profile 337

pasireotide ER - Drug Profile 343

PCA-062 - Drug Profile 347

pembrolizumab - Drug Profile 348

pralatrexate - Drug Profile 394

Recombinant Protein 1 for Oncology - Drug Profile 400

rucaparib camsylate - Drug Profile 401

RXDX-106 - Drug Profile 410

S-222611 - Drug Profile 412

S-588410 - Drug Profile 414

sacituzumab - Drug Profile 416

SDS-eCAR - Drug Profile 427

SHR-1210 - Drug Profile 428

sirotinib - Drug Profile 430

Small Molecule to Target LGR5 for Esophageal Adenocarcinoma - Drug Profile 431

Small Molecules to Inhibit Histone Demethylase for Esophageal Cancer - Drug Profile 432

SMYD2-BAY02 - Drug Profile 433

STNM-01 - Drug Profile 434

TBI-1201 - Drug Profile 436

TBL-0805E - Drug Profile 438

TGR-1202 - Drug Profile 439

tisotumab vedotin - Drug Profile 448

tivantinib - Drug Profile 450

TLC-388 - Drug Profile 456

triciribine phosphate - Drug Profile 458

Vaccine for Advanced Squamous Cell Carcinoma of Esophagus and Adenocarcinoma of Colon - Drug Profile 462

Vaccine for Oncology - Drug Profile 463

Vaccine for Oncology - Drug Profile 464

varlitinib - Drug Profile 465

VIMO-001 - Drug Profile 468

YQ-23 - Drug Profile 469

Esophageal Cancer - Dormant Projects 470

Esophageal Cancer - Discontinued Products 473

Esophageal Cancer - Product Development Milestones 474

Featured News & Press Releases 474

Appendix 486

Methodology 486

Coverage 486

Secondary Research 486

Primary Research 486

Expert Panel Validation 486

Contact Us 486

Disclaimer 487

List of Tables

List of Tables

Number of Products under Development for Esophageal Cancer, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Esophageal Cancer – Pipeline by Adaptimmune Therapeutics Plc, H1 2017

Esophageal Cancer – Pipeline by ADC Therapeutics Sarl, H1 2017

Esophageal Cancer – Pipeline by Aduro BioTech Inc, H1 2017

Esophageal Cancer – Pipeline by Advaxis Inc, H1 2017

Esophageal Cancer – Pipeline by Advenchen Laboratories LLC, H1 2017

Esophageal Cancer – Pipeline by Almac Discovery Ltd, H1 2017

Esophageal Cancer – Pipeline by Amgen Inc, H1 2017

Esophageal Cancer – Pipeline by Aprea AB, H1 2017

Esophageal Cancer – Pipeline by ArQule Inc, H1 2017

Esophageal Cancer – Pipeline by Array BioPharma Inc, H1 2017

Esophageal Cancer – Pipeline by Aslan Pharmaceuticals Pte Ltd, H1 2017

Esophageal Cancer – Pipeline by ATLAB Pharma SAS, H1 2017

Esophageal Cancer – Pipeline by Bayer AG, H1 2017

Esophageal Cancer – Pipeline by BeiGene Ltd, H1 2017

Esophageal Cancer – Pipeline by Beta Pharma Inc, H1 2017

Esophageal Cancer – Pipeline by Boehringer Ingelheim GmbH, H1 2017

Esophageal Cancer – Pipeline by Bristol-Myers Squibb Company, H1 2017

Esophageal Cancer – Pipeline by CBT Pharmaceuticals Inc, H1 2017

Esophageal Cancer – Pipeline by Celgene Corp, H1 2017

Esophageal Cancer – Pipeline by Celldex Therapeutics Inc, H1 2017

Esophageal Cancer – Pipeline by Cellectar Biosciences Inc, H1 2017

Esophageal Cancer – Pipeline by CellSeed Inc, H1 2017

Esophageal Cancer – Pipeline by Clovis Oncology Inc, H1 2017

Esophageal Cancer – Pipeline by Cyclacel Pharmaceuticals Inc, H1 2017

Esophageal Cancer – Pipeline by Eli Lilly and Company, H1 2017

Esophageal Cancer – Pipeline by F. Hoffmann-La Roche Ltd, H1 2017

Esophageal Cancer – Pipeline by Genmab A/S, H1 2017

Esophageal Cancer – Pipeline by GlaxoSmithKline Plc, H1 2017

Esophageal Cancer – Pipeline by Glycotope GmbH, H1 2017

Esophageal Cancer – Pipeline by Hutchison China MediTech Ltd, H1 2017

Esophageal Cancer – Pipeline by Ignyta Inc, H1 2017

Esophageal Cancer – Pipeline by Immunocore Ltd, H1 2017

Esophageal Cancer – Pipeline by ImmunoFrontier Inc, H1 2017

Esophageal Cancer – Pipeline by Immunomedics Inc, H1 2017

Esophageal Cancer – Pipeline by Intezyne Technologies Inc, H1 2017

Esophageal Cancer – Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2017

Esophageal Cancer – Pipeline by Johnson & Johnson, H1 2017

Esophageal Cancer – Pipeline by Komipharm International Co Ltd, H1 2017

Esophageal Cancer – Pipeline by Leap Therapeutics Inc, H1 2017

Esophageal Cancer – Pipeline by MaxiVAX SA, H1 2017

Esophageal Cancer – Pipeline by Mebiopharm Co Ltd, H1 2017

Esophageal Cancer – Pipeline by MedImmune LLC, H1 2017

Esophageal Cancer – Pipeline by Merck & Co Inc, H1 2017

Esophageal Cancer – Pipeline by Novartis AG, H1 2017

Esophageal Cancer – Pipeline by Omeros Corp, H1 2017

Esophageal Cancer – Pipeline by Oncolys BioPharma Inc, H1 2017

Esophageal Cancer – Pipeline by OncoMed Pharmaceuticals Inc, H1 2017

Esophageal Cancer – Pipeline by Ono Pharmaceutical Co Ltd, H1 2017

Esophageal Cancer – Pipeline by Puma Biotechnology Inc, H1 2017

Esophageal Cancer – Pipeline by Rhizen Pharmaceuticals SA, H1 2017

Esophageal Cancer – Pipeline by Shionogi & Co Ltd, H1 2017

Esophageal Cancer – Pipeline by Spectrum Pharmaceuticals Inc, H1 2017

Esophageal Cancer – Pipeline by Stelic Institute & Co Inc, H1 2017

Esophageal Cancer – Pipeline by Supratek Pharma Inc, H1 2017

Esophageal Cancer – Pipeline by Symphogen A/S, H1 2017

Esophageal Cancer – Pipeline by Taiho Pharmaceutical Co Ltd, H1 2017

Esophageal Cancer – Pipeline by Taiwan Liposome Company Ltd, H1 2017

Esophageal Cancer – Pipeline by Takara Bio Inc, H1 2017

Esophageal Cancer – Pipeline by Transgene Biotek Ltd, H1 2017

Esophageal Cancer – Pipeline by VioQuest Pharmaceuticals Inc, H1 2017

Esophageal Cancer – Pipeline by XuanZhu Pharma Co Ltd, H1 2017

Esophageal Cancer – Dormant Projects, H1 2017

Esophageal Cancer – Dormant Projects, H1 2017 (Contd..1), H1 2017

Esophageal Cancer – Dormant Projects, H1 2017 (Contd..2), H1 2017

Esophageal Cancer – Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Esophageal Cancer, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Top 10 Routes of Administration, H1 2017

Number of Products by Stage and Top 10 Routes of Administration, H1 2017

Number of Products by Top 10 Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports